Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
N Thon, S Kreth, FW Kreth - OncoTargets and therapy, 2013 - Taylor & Francis
The identification of molecular genetic biomarkers considerably increased our current
understanding of glioma genesis, prognostic evaluation, and treatment planning. In …
understanding of glioma genesis, prognostic evaluation, and treatment planning. In …
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges
A Mansouri, LD Hachem, S Mansouri, F Nassiri… - Neuro …, 2019 - academic.oup.com
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally
poor prognosis. The emergence of molecular biomarkers has had a significant impact on …
poor prognosis. The emergence of molecular biomarkers has had a significant impact on …
MGMT methylation status: the advent of stratified therapy in glioblastoma?
P Hau, R Stupp, ME Hegi - Disease markers, 2007 - Wiley Online Library
Glioblastomas are the most malignant gliomas with median survival times of only 15 months
despite modern therapies. All standard treatments are palliative. Pathogenetic factors are …
despite modern therapies. All standard treatments are palliative. Pathogenetic factors are …
MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study
M Szylberg, P Sokal, P Śledzińska, M Bebyn… - Biomedicines, 2022 - mdpi.com
Glioblastoma is the most malignant central nervous system tumor, which represents 50% of
all glial tumors. The understanding of glioma genesis, prognostic evaluation, and treatment …
all glial tumors. The understanding of glioma genesis, prognostic evaluation, and treatment …
Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma
G Brigliadori, F Foca, M Dall'Agata, C Rengucci… - Journal of neuro …, 2016 - Springer
Despite advances in the treatment of glioblastoma (GBM), median survival is 12–15 months.
O 6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status is …
O 6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status is …
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
G Reifenberger, B Hentschel, J Felsberg… - … journal of cancer, 2012 - Wiley Online Library
Abstract O6‐methylguanine‐DNA‐methyltransferase (MGMT) promoter methylation
identifies a subpopulation of glioblastoma patients with more favorable prognosis and …
identifies a subpopulation of glioblastoma patients with more favorable prognosis and …
[HTML][HTML] The T genotype of the MGMT C> T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival …
KL McDonald, RW Rapkins, J Olivier, L Zhao… - European journal of …, 2013 - Elsevier
Clinical studies in patients with newly diagnosed glioblastoma treated with temozolomide
have shown that the methylation status of the O6-methylguanine-DNA methyltransferase …
have shown that the methylation status of the O6-methylguanine-DNA methyltransferase …
MGMT gene promoter methylation status–assessment of two pyrosequencing kits and three methylation-specific PCR methods for their predictive capacity in …
LE Johannessen, P Brandal… - Cancer genomics & …, 2018 - cgp.iiarjournals.org
Background: Although methylation of the O6-methylguanine-DNA methyltransferase
(MGMT) gene promoter predicts response to temozolomide in patients with glioblastoma, no …
(MGMT) gene promoter predicts response to temozolomide in patients with glioblastoma, no …
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma …
S Lalezari, AP Chou, A Tran, OE Solis… - Neuro …, 2013 - academic.oup.com
Background Promoter methylation of the DNA repair gene, O-6-methylguanine-DNA
methyltransferase (MGMT), is associated with improved treatment outcome for newly …
methyltransferase (MGMT), is associated with improved treatment outcome for newly …
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical …
ME Hegi, E Genbrugge, T Gorlia, R Stupp… - Clinical Cancer …, 2019 - AACR
Purpose: The methylation status of the O6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …